Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
4.16 USD | 0.00% | -6.09% | -30.55% |
Kurzporträt
Mitarbeiterzahl: 536
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Oral Small Molecule and Protein Therapeutics
100,0
%
| 271 | 100,0 % | 331 | 100,0 % | +22.37% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
87,0
%
| - | - | 288 | 87,0 % | - |
Non-United States
11,4
%
| - | - | 38 | 11,4 % | - |
Global
1,6
%
| 271 | 100,0 % | 5 | 1,6 % | -98.00% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01.01.07 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 02.04.20 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 01.03.22 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20.09.19 |
Philip George
PRN | Corporate Officer/Principal | - | 01.09.22 |
Corporate Officer/Principal | - | 01.01.15 | |
Charles Gayer
PRN | Corporate Officer/Principal | 53 | 01.08.15 |
Human Resources Officer | - | 01.11.18 | |
Salisa Hauptmann
LAW | General Counsel | - | 01.01.21 |
Corporate Officer/Principal | 61 | 01.01.23 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 27.02.20 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01.01.07 |
Director/Board Member | 60 | 26.07.21 | |
Stephen Aselage
BRD | Director/Board Member | 73 | 04.01.19 |
Director/Board Member | 69 | 10.10.11 | |
Nancy Hutson
CHM | Chairman | 74 | 20.01.12 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20.09.19 |
Steven Galson
BRD | Director/Board Member | 67 | 01.09.21 |
Theresa Heggie
BRD | Director/Board Member | 63 | 03.12.18 |
Amy McKee
BRD | Director/Board Member | 52 | 20.09.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 206 330 603 | 199 798 093 ( 96,83 %) | 0 | 96,83 % |
Unternehmenskontakt
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 200
27703-8457, Durham
+919 859 1302
http://www.biocryst.comSektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-30.55% | 858 Mio. | |
-2.31% | 103 Mrd. | |
+0.56% | 95.28 Mrd. | |
+1.69% | 22.15 Mrd. | |
-17.37% | 21.02 Mrd. | |
-9.30% | 18.15 Mrd. | |
-41.01% | 16.74 Mrd. | |
-14.85% | 16.05 Mrd. | |
+3.21% | 13.68 Mrd. | |
+33.54% | 12.17 Mrd. |
- Börse
- Aktien
- 896047 Aktie
- Unternehmen BioCryst Pharmaceuticals, Inc.